Plain-English translation of NCT07199218 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called terpenes-enriched Cannabis Oil T1/C28 to see if it can help children with autism spectrum disorder. The medication contains cannabidiol (CBD), a natural plant compound that does not make you feel high, combined with a very small amount of tetrahydrocannabinol (THC) and other plant compounds called terpenes. Researchers believe this combination may help reduce behavior problems, improve social interaction, and enhance quality of life in children with autism.
Current medications do not treat the core symptoms of autism and can cause unwanted side effects. Early research suggests that this medication may work differently in children with autism by calming brain overactivity and reducing inflammation, offering a potentially safer way to help with autism-related challenges.
You likely qualify if…
You likely don't qualify if…
Your child would visit the clinic regularly over 16 weeks total. For the first 8 weeks, half of participants will receive the study medication by mouth, while the other half will receive a placebo (inactive oil) that looks and tastes the same—neither you nor the research team will know which one your child is receiving. After 8 weeks, all participants will receive the active medication for another 8 weeks. Throughout the study, the research team will monitor safety through clinic visits, questionnaires, physical exams, and blood tests to ensure the treatment is working well and not causing harm.
AI-generated summary from trial data · Jul 17, 2026 · Not medical advice
Israel